Evonetix — Cyborg Score 7/10

Solid
DNA synthesis platforms

Strategic Profile

The platform uses silicon arrays for DNA synthesis of genes having high GC content, enabled by semiconductor microfabrication which enables various miniaturized reaction sites. CEO Colin McCracken notes the ultimate goal is to provide a desktop synthesiser to all labs for researchers to utilize, with recent installation at Imperial College London representing a significant step forward in delivering on this vision.

Cyborg Score Rationale

Evonetix has raised a total funding of $70M over 7 rounds with strong venture backing and demonstrable technology deployment. Recent milestone includes installation at Imperial College London following successful chip-synthesised DNA delivery and testing at University of Cambridge. Revenue remains pre-commercial at scale, positioning the company in controlled growth phase.

Top Insights

  • Proprietary silicon array technology uses semiconductor microfabrication to enable miniaturized reaction sites for DNA synthesis
  • Platform comprises patented semiconductor chip designs and proprietary, thermally controlled synthesis chemistry for novel chemistry approaches and process control
  • June 2026 installation at Imperial College London addresses bottleneck in turnaround time and costs for accessing long synthetic DNA
  • Enabling applications in healthcare, sustainability, agriculture, and manufacturing for engineering biology and related fields

Named Competitors

  • DNA Script SYNTAX — Enzymatic benchtop DNA printer for custom DNA oligos and research applications
  • Molecular Assemblies DNA — Enzymatic DNA synthesis for therapeutics, vaccines, agriculture, and nanotechnology
  • Oxford Nanopore Technologies — Nanopore-based DNA sequencing and long-read genomics
  • Pacific Biosciences — Long-read sequencing systems and genomics platforms
  • Quantapore — DNA sequencing and analysis technology

Recent Developments

  • (June 2026) Installed first DNA synthesis development platform at Imperial College London
  • (February 2023) Completed $24 million Series B financing, extending total Series B funding to over $54 million
  • (2015) Founded by Raymond Anthony Edgson, Joseph Brennan, Matthew Hayes with origins from Cambridge Consultants and Providence Investment Company

Open the full interactive Evonetix report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →